# Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%

> **NCT06539637** · EARLY_PHASE1 · RECRUITING · sponsor: **DHS Consulting** · enrollment: 20 (estimated)

## Conditions studied

- Cataract

## Interventions

- **COMBINATION_PRODUCT:** OMIDRIA (*Registered Product) {10.16 mg/mL (1% w/v) of phenylephrine and 2.88 mg/mL (0.3% w/v) of ketorolac}
- **OTHER:** Ketorolac Tromethamine {TORADOL} (0.5%) - Topical Eyedrop

## Key facts

- **NCT ID:** NCT06539637
- **Lead sponsor:** DHS Consulting
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-01
- **Primary completion:** 2025-11
- **Final completion:** 2026-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06539637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06539637, "Ketorolac Levels in Vitreous and Aqueous Samples From Patients Undergoing Combined Cataract and Pars Plana Vitrectomy Surgeries With and Without Intracameral Phenylephrine 1.0% / Ketorolac 0.3%". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06539637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*